Clinical Trials Logo

Clinical Trial Summary

Extent of use of generics immunosuppressive drugs in clinical practice after lung transplantation


Clinical Trial Description

Solid organ transplant recipients are treated with immunosuppressive drugs to prevent rejection of their grafts. The most frequently important maintenance immunosuppressive drugs in Europe are calcineurin inhibitors.

For a number of these compounds drug patents have expired in recent years and generic formulations have entered the market. There is considerable debate regarding the efficacy and safety of generic drug substitution in solid organ recipients. ;


Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms

  • Immunosuppressive After Lung Transplantation

NCT number NCT01889017
Study type Observational
Source Hannover Medical School
Contact Jens Gottlieb, MD
Phone 0049511-532
Email gottlieb.jens@mh-hannover.de
Status Recruiting
Phase N/A
Start date July 2013
Completion date September 2014